Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-risk Osteosarcoma.

Trial Profile

Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-risk Osteosarcoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Mifamurtide (Primary)
  • Indications Osteosarcoma
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2013 Planned end date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top